Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:58 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 99 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Low Dose Corticosteroids Clear all

Conditions: X-Linked Retinitis Pigmentosa
Interventions: AGTC-501 (high dose and standard corticosteroid regimen), AGTC-501 (low dose and standard corticosteroid regimen), AGTC-501 (high dose and modified corticosteroid regimen); Biological
Lead sponsor: Beacon Therapeutics; Industry
Eligibility: 12 Years and older · Male only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 7
States / cities: Jacksonville, Florida • Miami, Florida • Boston, Massachusetts + 4 more

Conditions: Asthma, Pediatric ALL
Interventions: budesonide, beclomethasone; Drug
Lead sponsor: New York City Health and Hospitals Corporation; Other
Eligibility: Up to 18 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Metastatic Castration-resistant Prostate Cancer, Metastatic Breast Cancer
Interventions: Abiraterone acetate, Prednisone; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: Not listed
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2021
U.S. locations: 10
States / cities: Aurora, Colorado • Marrero, Louisiana • Boston, Massachusetts + 7 more

Conditions: Total Knee Arthroplasty
Interventions: Hydrocortisone, Placebo; Drug
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 50 Years to 90 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Respiratory Distress Syndrome (RDS), Bronchopulmonary Dysplasia (BPD)
Interventions: Betamethasone; Drug
Lead sponsor: Khang Nguyen; Other
Eligibility: Up to 28 Weeks
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Valhalla, New York

Conditions: Asthma
Interventions: Procedure: Investigational Procedures; Other
Lead sponsor: Sanofi; Industry
Eligibility: 6 Years and older
Enrollment: 2,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 63
States / cities: Bessemer, Alabama • Chandler, Arizona • Mesa, Arizona + 49 more

Conditions: Graft-versus-host Disease (GVHD)
Interventions: Ruxolitinib, Extracorporeal photopheresis (ECP), Low-dose methotrexate (MTX), Mycophenolate mofetil (MMF), mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus), Infliximab, Rituximab, Pentostatin, Imatinib, Ibrutinib; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 12 Years and older
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 38
States / cities: Tucson, Arizona • Duarte, California • La Jolla, California + 28 more

Conditions: Atopic Dermatitis
Interventions: Dupilumab, Placebo (for Dupilumab), Topical Corticosteroid (TCS); Drug · Other
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 740 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 50
States / cities: Phoenix, Arizona • Hot Springs, Arkansas • Little Rock, Arkansas + 47 more

Conditions: Knee Osteoarthritis
Interventions: Methylprednisolone acetate, taVNS; Drug · Device
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 45 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Decatur, Georgia

Conditions: Asthma
Interventions: FP 100, GSK2190915 100, GSK2190915 300, montelukast, placebo, FP/SAL 100/50; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older · Female only
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 32
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Huntington Beach, California + 28 more

Conditions: Atopic Dermatitis
Interventions: Nemolizumab, Placebo; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years and older
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 26
States / cities: Birmingham, Alabama • Fort Smith, Arkansas • Beverly Hills, California + 21 more

Conditions: Renal Transplant Failure and Rejection
Interventions: Siplizumab, Rabbit anti-thymocyte globulin; Drug
Lead sponsor: ITB-Med LLC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 19
States / cities: Los Angeles, California • Sacramento, California • Tampa, Florida + 14 more

Conditions: Shift Work Schedule, Circadian Rhythm, Insulin Resistance, Circadian Misalignment
Interventions: Metyrapone And Hydrocortisone, Dextrose, insulin; Drug
Lead sponsor: Washington State University; Other
Eligibility: 18 Years to 45 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Spokane, Washington

Conditions: Cannabis Intoxication
Interventions: Cannabis, Pregnenolone 250 mg, Pregnenolone 500 mg, Placebo, Placebo brownie; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Atopic Dermatitis
Interventions: Placebo, Upadacitinib, Topical corticosteroids (TCS); Drug
Lead sponsor: AbbVie; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 1,533 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2030
U.S. locations: 59
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 51 more

Conditions: Asthma
Interventions: Placebo, Fluticasone propionate, BI 54903; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 37
States / cities: Fountain Valley, California • Fullerton, California • Long Beach, California + 33 more

Conditions: Lung Neoplasm
Interventions: R-DXD, I-DXD, Docetaxel, Rescue Medications, Rescue Medication; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 4
States / cities: Lexington, Kentucky • Baltimore, Maryland • Dallas, Texas + 1 more

Conditions: Kidney Transplantation, Graft Rejection
Interventions: Everolimus, Mycophenolic Acid (MPA), Cyclosporine A (CsA), Basiliximab, Corticosteroids; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 833 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Pituitary Adenoma, Pituitary Diseases
Interventions: hydrocortisone, dexamethasone; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Asthma
Interventions: FS MDPI, Fp MDPI, Placebo MDPI, albuterol/salbutamol, Beclomethasone dipropionate; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 787 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 76
States / cities: Birmingham, Alabama • Glendale, Arizona • Cypress, California + 64 more

Conditions: End-stage Liver Disease, Renal Insufficiency, Renal Failure
Interventions: mycophenolate mofetil, placebo medication; Drug · Other
Lead sponsor: Baylor College of Medicine; Other
Eligibility: Up to 16 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions: asparaginase, cytarabine, daunorubicin hydrochloride, methotrexate, therapeutic hydrocortisone, thioguanine; Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 21 Years
Enrollment: 254 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2012
U.S. locations: 209
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 151 more

Conditions: Delayed Graft Function
Interventions: Everolimus, Tacrolimus, Mycophenolate mofetil (MMF/MPA); Drug
Lead sponsor: Matthew Cooper; Other
Eligibility: 18 Years to 65 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Asthma
Interventions: Roflumilast; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years to 70 Years
Enrollment: 2,054 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Cities in Georgia, Georgia

Search by objective public record fields.

A Study Comparing Two Doses of AGTC-501 in Male Participants With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (DAWN)

Inhaled Steroids for Pediatric Asthma at Pediatric Emergency Medicine Discharge

A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate

Effect of Low Dose Corticosteroids on Perioperative Markers of Thrombosis and Fibrinolysis in Total Knee Arthroplasty

Can Betamethasone Given After Birth Help Extremely Premature Babies Come Off Breathing Support Safely and Effectively?

A Study Evaluating Disease Characteristics and Outcomes in Participants With Asthma in Routine Clinical Practice

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis

taVNS in Veterans With Knee OA (AVAHCS)

Safety and Efficacy Study of Adding GSK2190915 to Low Dose Inhaled Corticosteroid Treatment for Asthma Subjects > or = 12 Years of Age

Dose-ranging Study of Nemolizumab in Atopic Dermatitis

A Study Comparing Siplizumab With Rabbit Anti-Thymocyte Globulin to Help the Body Accept a Kidney Transplant

Sleep Loss and Circadian Misalignment - Mechanisms of Insulin Resistance

Pregnenolone as a Treatment for Cannabis Intoxication

A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Medium Dose Inhaled Corticosteroid (ICS).

Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)

Efficacy and Safety Study of Everolimus Plus Reduced Cyclosporine Versus Mycophenolic Acid Plus Cyclosporine in Kidney Transplant Recipients

Peri-Operative Steroid Management in Patients

Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Adolescent and Adult Patients With Persistent Asthma

Trial of Calcineurin Inhibitor-Sparing Immunosuppression Regimen in Pediatric Liver Transplantation

Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome

A Pilot Study Comparing the Safety and Efficacy of Everolimus With Other Medicines in Recipients of ECD/DCD Kidneys

Efficacy and Safety of Oral Roflumilast Taken With Low Dose Inhaled Corticosteroids in Patients With Asthma (12 to 70 y) (BY217/M2-013)